Friday, June 17, 2011 3:18:17 PM
You may think that no one else has the capacity to get approval, but that is not how MNTA is doing its financial planning. At least that is how it presented itself very clearly at the annual meeting. Maybe it was all for show, but it was a matter of signifant emphasis (especially in talking about the need for novel drugs in its portofolio). Wheeler said several times that generic competition is always a concern. Again, it might have been to offset the Palo Alto demand for share price support, but it was clearly said to be a concern long term.
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
